Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul:169:105689.
doi: 10.1016/j.phrs.2021.105689. Epub 2021 May 23.

Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation

Gissette Reyes-Soffer  1 , Marit Westerterp  2
Affiliations
Review

Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation

Gissette Reyes-Soffer et al. Pharmacol Res. 2021 Jul.

Abstract

Genome wide association, epidemiological, and clinical studies have established high lipoprotein(a) [Lp(a)] as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) is an apoB100 containing lipoprotein covalently bound to apolipoprotein(a) [apo(a)], a glycoprotein. Plasma Lp(a) levels are to a large extent determined by genetics. Its link to cardiovascular disease (CVD) may be driven by its pro-inflammatory effects, of which its association with oxidized phospholipids (oxPL) bound to Lp(a) is the most studied. Various inflammatory conditions, such as rheumatoid arthritis (RA), systemic lupus erythematosus, acquired immunodeficiency syndrome, and chronic renal failure are associated with high Lp(a) levels. In cases of RA, high Lp(a) levels are reversed by interleukin-6 receptor (IL-6R) blockade by tocilizumab, suggesting a potential role for IL-6 in regulating Lp(a) plasma levels. Elevated levels of IL-6 and IL-6R polymorphisms are associated with CVD. Therapies aimed at lowering apo(a) and thereby reducing plasma Lp(a) levels are in clinical trials. Their results will determine if reductions in apo(a) and Lp(a) decrease cardiovascular outcomes. As we enter this new arena of available treatments, there is a need to improve our understanding of mechanisms. This review will focus on the role of Lp(a) in inflammation and CVD.

Keywords: Atherosclerosis; Cardiovascular diseases; Inflammation; Lipoprotein(a).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

None.

References

    1. Tsimikas SFS, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L, NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis, J. Am. Coll. Cardiol 71 (2) (2018) 177–192. - PMC - PubMed
    1. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Lesnik P, Masana L, Reiner Z, Taskinen M-R, Tokgözoglu L, Tybjærg-Hansen A, Panel aEASC. Lipoprotein(a) as a cardiovascular risk factor: current status, Eur. Heart J 31 (2010) 2844–2853. - PMC - PubMed
    1. von Zychlinski A, Williams M, McCormick S, Kleffmann T, Absolute quantification of apolipoproteins and associated proteins on human plasma lipoproteins, J. Proteom 106 (2014) 181–190. - PubMed
    1. Kostner KM, Kostner GM, Lipoprotein (a): a historical appraisal, J. Lipid Res 58 (1) (2017) 1–14. - PMC - PubMed
    1. White AL, Rainwater DL, Hixson JE, Estlack LE, Lanford RE, Intracellular processing of apo(a) in primary baboon hepatocytes, Chem. Phys. Lipids 67–68 (1994) 123–133. - PubMed

Publication types